• March 12, 2026
  • Corporate
  • Ecosystem

  Have Fun Exploring Sleep with Pokémon!
  Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration

• March 11, 2026
  • R&D
  • Products

  Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting

• March 2, 2026
  • R&D
  • Products

  WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
  This is the first positive Phase 3 trial of a multi-targeted tyrosine kinase inhibitor in combination with a HIF-2 alpha inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor
  
  Based on these data, the U.S. FDA accepts for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC

• February 16, 2026
  • R&D

  Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

• February 9, 2026
  • Corporate

  Eisai Announces Appointment of Corporate Officers

View All

• February 10, 2026
  • Global Health
  • Human Resources

  World Neglected Tropical Disease (NTD) Day (January 30) Internal Awareness Event

• January 30, 2026
  • Patients and People
  • Global Health

  Engaging with Mycetoma Patients and the Current Status in Kenya
  Kenya Trip Report

• December 23, 2025
  • Global Health
  • Human Resources

  Transportation of Investigational Drugs for Mycetoma During Armed Conflict
  A Year and a Half of Effort With the Dedication of Many Stakeholders to Complete Shipment

• November 21, 2025
  • Patients and People
  • Global Health

  Call for Support of Japanese Corporate Activities and ODA in the Global Health Sector
  Letter of Request Delivered to Mr. Toshimitsu Motegi, Minister of Foreign Affairs

• May 21, 2025
  • Patients and People
  • Global Health

  Call for Support of Japanese Corporate Activities and ODA in the Global Health Sector
  Letter of Request Delivered to Mr. Takamaro Fukuoka, Minister of Health, Labour and Welfare

View All

• February 26, 2026

  Eisai’s Kawashima Plant Honored with “Gifu Decarbonization Top Runner Award”
  - Recognized for Proactive Initiatives to Reduce Greenhouse Gas Emissions -

• February 20, 2026

  Eisai Selected for “Thought Leaders of Human Capital 2025” and “Human Capital Management Excellence 2025 Gold Award” for Third Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives

• November 25, 2025

  Notice on Discontinuation of Receiving Emails with Password-Protected Attachments

• February 19, 2025

  Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”

• October 3, 2024

  EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024

View All